Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 7090 results found since Jan 2013.

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms.
Abstract Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. The detailed mechanism underlying R-CHOP resistance has not been well defined. For this review, we conducted a thorough search for literature and clinical trials involving DLBCL resistance. We discussed DLBCL biology, epigenetics, and aberrant signaling of the B-cell receptor (BCR), phosphatidylinositol 3-kinase ...
Source: Chinese Medical Journal - December 8, 2020 Category: General Medicine Authors: Wang L, Li LR Tags: Chin Med J (Engl) Source Type: research

Disease-Modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry
CONCLUSIONS: It is clinically important for oral health clinicians to be aware of possible drug interactions between DMARDs and the drugs commonly prescribed in dentistry to prevent potential adverse reactions and avoid endangering the patient.PMID:33877648 | DOI:10.26355/eurrev_202104_25536
Source: European Review for Medical and Pharmacological Sciences - April 20, 2021 Category: Drugs & Pharmacology Authors: C Mu ñoz-Martínez M Segura-Puertas G G ómez-Moreno Source Type: research

Granulomatosis with polyangiitis in a patient with polydipsia, facial nerve paralysis, and severe otologic complaints: a case report and review of the  literature
ConclusionGranulomatosis with polyangiitis is a highly variable disease, commonly involving the upper airways, but that may present with symptoms solely related to the pituitary gland. Clinicians should have a low threshold to investigate for granulomatosis with polyangiitis in patients with therapy-resistant otorrhea. Patients may present with a complex set of symptoms, and integrating different specialists when additional symptoms occur may lead to faster diagnosis.
Source: Journal of Medical Case Reports - July 28, 2022 Category: General Medicine Source Type: research

Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
CONCLUSIONS: This study suggests that Pola + R-CHP is a cost-effective treatment for previously untreated DLBCL in Japan under the public health insurance system.PMID:37656225 | DOI:10.1080/13696998.2023.2254162
Source: Journal of Medical Economics - September 1, 2023 Category: Health Management Authors: Takashi Mizuoka Hiroyuki Sakamaki Shigeo Fuji Shota Saito Tatsunori Murata Shinya Ohno Naoki Inubashiri Tomoha Oshima Kazuhito Yamamoto Source Type: research

Lupus nephritis - An update on disparities affecting african americans
J Natl Med Assoc. 2022 May 17:S0027-9684(22)00086-4. doi: 10.1016/j.jnma.2022.05.005. Online ahead of print.ABSTRACTLupus Nephritis is a complex clinical manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. It disproportionately affects minorities, especially African Americans (AA) with higher rates of progression to end stage kidney disease. Several factors are implicated including genetic predisposition to both SLE and chronic kidney disease, social determinants of health such as income inequality, education disparities, social isolation/lack of support, health care acc...
Source: Journal of the National Medical Association - May 20, 2022 Category: General Medicine Authors: Gilda M Portalatin Surafel K Gebreselassie Shane A Bobart Source Type: research